Friday 6 November 2026
Export PEN’s income statement to Excel — free account
Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
319.20
1.91
−0.59%
Follow PEN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
79.72 | 77.20 | 74.97 | 68.03 |
+8 more quarters Free account |
P/S ratio |
8.04 | 8.26 | 8.87 | 8.62 | |
P/FCF ratio |
62.62 | 57.55 | 60.62 | 69.17 | |
P/Operating CF |
302.19 | 269.64 | 148.29 | 139.91 | |
P/B ratio |
7.92 | 8.12 | 8.75 | 8.48 | |
Price to Tangible BV |
8.89 | 9.15 | 9.91 | 9.64 | |
EV/Sales |
7.62 | 7.83 | 8.46 | 8.25 | |
EV/EBITDA |
56.79 | 57.64 | 60.25 | 56.00 | |
EV/Operating CF |
45.54 | 42.43 | 44.46 | 48.50 | |
EV/FCF |
59.36 | 54.59 | 57.83 | 66.17 | |
Quick Ratio |
3.72 | 3.63 | 3.77 | 4.01 | |
Current Ratio |
5.89 | 5.75 | 6.02 | 6.64 | |
Net Debt/EBITDA |
(11.65) | (13.70) | (13.91) | (8.23) | |
Debt/Assets |
0.94% | 0.99% | 1.07% | 1.13% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.83 | 0.82 | 0.83 | 0.84 | |
Operating CF/Net income |
0.98 | 1.32 | 2.67 | 1.83 | |
Capex/Depreciation |
(2.76) | (2.41) | (2.99) | (4.13) | |
Research and Development Expense of Revenue |
6.18% | 6.51% | 5.97% | 5.66% | |
Selling, General and Administrative Expense of Revenue |
49.79% | 50.89% | 51.45% | 46.99% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
3.62% | 3.50% | 3.91% | 3.96% | |
Graham Net Nets |
0.07 | 0.07 | 0.07 | 0.07 | |
Graham Number |
60.09 | 59.83 | 60.81 | 61.42 | |
Earnings Yield |
1.25% | 1.30% | 1.33% | 1.47% | |
Free Cash Flow Yield |
1.60% | 1.74% | 1.65% | 1.45% | |
Revenue per Share |
10.41 | 9.91 | 9.54 | 9.90 | |
Operating CF per Share |
1.05 | 1.17 | 2.21 | 2.22 | |
Capex per Share |
(0.38) | (0.34) | (0.35) | (0.47) | |
Free Cash Flow per Share |
0.67 | 0.83 | 1.87 | 1.75 | |
Cash per Share |
17.10 | 16.74 | 15.68 | 14.00 | |
Shareholders Equity per Share |
40.19 | 38.90 | 37.53 | 36.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
40.19 | 38.90 | 37.53 | 36.68 | |
Free Cash Flow |
26.40 | 32.54 | 73.30 | 68.05 | |
Working Capital |
1,142.82 | 1,110.35 | 1,063.68 | 1,033.55 | |
Capital Expenditures |
(15.11) | (13.54) | (13.67) | (18.43) | |
Net Current Asset Value |
935.04 | 900.17 | 850.78 | 817.77 | |
EV/EBIT |
62.82 | 62.92 | 65.74 | 61.17 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.05 | |
Price to Operating Income |
66.28 | 66.33 | 68.92 | 63.94 | |
| Other line items | |||||
Average Receivables |
189.32 | 182.97 | 175.64 | 178.84 | |
Average Payables |
35.89 | 36.42 | 37.41 | 33.03 | |
Average Inventory |
445.75 | 435.14 | 427.20 | 419.14 | |
Average Assets |
1,884.74 | 1,824.77 | 1,745.87 | 1,679.85 | |
Average Common Equity |
1,471.10 | 1,412.36 | 1,343.35 | 1,289.27 |
Columns are period end dates · fundamentals updated 2 Nov 2026